Recludix Pharma Announces FDA Clearance of Investigational New Drug Application for REX-8756, an Oral STAT6 Inhibitor, to Enter into the Clinic
REX-8756 is a potent and selective oral STAT6 inhibitor that has shown complete 100% pathway inhibition and potent efficacy in preclinical models of asthma, acute lung inflammation and dermatitis Efficacy comparable to anti-IL-4/IL-13 antibody combination control with a favorable tolerability profile in preclinical models Being advanced under a strategic partnership with Sanofi, where Recludix has […]